Insmed (NASDAQ:INSM) Sets New 1-Year High After Analyst Upgrade

Key Points

• Insmed's shares reached a new 52-week high after TD Cowen upgraded their price target from $154 to $193, indicating a buy rating on the stock.
• Multiple brokerages, including Jefferies and JPMorgan, have also raised their price targets for Insmed, contributing to a consensus rating of "Moderate Buy" among analysts.
• Insider trading activity included significant sales by the CFO and a director, with company insiders selling a total of 277,332 shares over the past ninety days.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) shares hit a new 52-week high on Thursday after TD Cowen raised their price target on the stock from $154.00 to $193.00. TD Cowen currently has a buy rating on the stock. Insmed traded as high as $150.16 and last traded at $149.78, with a volume of 1074161 shares changing hands. The stock had previously closed at $147.28.

Several other brokerages have also recently commented on INSM. Jefferies Financial Group boosted their price target on Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. JPMorgan Chase & Co. boosted their price target on Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a research note on Wednesday, August 20th. Guggenheim boosted their price target on Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research note on Monday, September 8th. William Blair started coverage on Insmed in a research note on Wednesday, August 20th. They issued an "outperform" rating for the company. Finally, Truist Financial boosted their price target on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Nineteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Insmed presently has a consensus rating of "Moderate Buy" and an average price target of $145.69.

Insider Activity

In other Insmed news, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the completion of the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director owned 262,675 shares in the company, valued at $38,190,318.25. The trade was a 3.67% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 277,332 shares of company stock valued at $33,842,327. 3.00% of the stock is owned by company insiders.

Institutional Trading of Insmed

Several large investors have recently made changes to their positions in INSM. Cullen Frost Bankers Inc. grew its holdings in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the last quarter. ORG Partners LLC grew its holdings in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 196 shares during the last quarter. Hilltop National Bank bought a new stake in shares of Insmed during the second quarter worth $28,000. FNY Investment Advisers LLC bought a new stake in shares of Insmed during the second quarter worth $33,000. Finally, NBC Securities Inc. bought a new stake in shares of Insmed during the first quarter worth $49,000.

Insmed Stock Performance

The firm has a fifty day moving average of $130.41 and a 200-day moving average of $97.89. The firm has a market cap of $31.68 billion, a P/E ratio of -26.24 and a beta of 1.03. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. Insmed's revenue was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.